Apotex Pharmachem Inc.

Apotex Inc.

Brantford Chemicals Inc.

Cameron L McPhail

Allan W Rey

Yajun Zhao

Gamini Weeratunga

Fan Wang

Probal Kanti Datta

Peter Garth Blazecka

Daqing Che

Zhi-Xian Wang

Prabhudas Bodhuri

Avedis Karadeolian

Carlos Zetina-Rocha

Stuart P Green

David A Stradiotto

Sammy Chris Duncan

Murali Kondamreddy

Nageib Mohamed

Eduardo Gustavo Cammisa

Kaarina K Milnes

Kevin Wade Kells

Randa E El-Haj

Krista Lyn Traynor

Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof.

Forms of vilazodone and processes for the preparation thereof

Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).

Solid forms of nilotinib hydrochloride

Provided for in the instant application are two additional forms of rifaximin, namely rifaximin polymorphic forms APO-III and APO-IV. Also provided are allegedly novel processes for preparing the previously disclosed rifaximin polymorphic forms APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused bybacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.

Polymorphic forms of rifaximin

Solid and crystalline forms of tofacitinib hydrochloride and tofacitinib hydrobromide, processes for the preparation thereof and processes for the use thereof in preparing tofacitinib citrate are provided.

Solid forms of tofacitinib salts

Provided is dexlansoprazole propylene glycolate hydrate. Polymorphic forms thereof are also provided. The dexlansoprazole propylene glycolate hydrate maybe such that the propylene glycol component is present in approximately equal proportions of (R) absolute configuration and (S) absolute configuration, or present in predominantly (R) absolute configuration, or predominantly (S) absolute configuration. Salts of dexlansoprazole are also provided. In particular, crystalline dexlansoprazole isopropylammonium salt and crystalline MTBE solvate of dexlansoprazole t-butylammonium salt are provided. Pharmaceutical formulations comprising dexlansoprazole propylene glycolate hydrate are also provided. Furthermore, processes for preparation of dexlansoprazole propylene glycolate hydrate are provided.

Forms of dexlansoprazole and processes for the preparation thereof

Provided are a cocrystal of Adefovir dipivoxil and nicotinamide as well as a cocrystal of Adefovir dipivoxil and salicylamide cocrystal and processes for the preparation thereof.

Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof

A novel form of Ibandronate sodium which is particularly suitable for pharmaceutical applications, and a process for preparing said novel form.

Ibandronate sodium propylene glycol solvate and processes for the preparation thereof

Process for the preparation of Ramipril

Growing community of inventors

Brantford, Canada

Cameron L McPhail